expert reaction to news that the FDA has approved the drug Cobenfy (KarXT) for schizophrenia
Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, London and South London and Maudsley NHS Foundation Trust, said:
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback